Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic, antiinflammatory drugs? Arguments against.

Journal:Thrombosis and Haemostasis
ISSN:0340-6245
DOI:http://dx.doi.org/10.1160/TH06-08-0445
Issue:2006: 96/4 (Oct) pp. 391-543
Pages:413-416

Archive
Article

Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic, antiinflammatory drugs? Arguments against.

Artur-Aron Weber 1, Thomas Hohlfeld 1, Sebastian Harder 2

1Institut für Pharmakologie und Klinische Pharmakologie, Universitätsklinikum Düsseldorf, Düsseldorf, Germany; 2Institut für Klinische Pharmakologie, Johann-Wolfgang Goethe-Universität Frankfurt am Main, Frankfurt am Main, Germany

Summary

The issue of the risk-benefit assessment of cyclooxygenase-2 (COX-2) inhibitors, as compared to traditional non-steroidal anti-inflammatory drugs (tNSAIDs), is far from being resolved. These compounds need to be carefully re-evaluated in order to avoid hasty conclusions, as it happened when COX-2 inhibitors were introduced into clinical practice. Several arguments support the concept, that COX-2 inhibitors remain a valuable therapeutic option at least for selected patients.

Keywords

inflammation, clinical studies, Haemostasis, lipid mediators, Arterial thrombosis

DOI

http://dx.doi.org/10.1160/TH06-08-0445
[Free download]

You may also be interested in...

1.
The risk of venous and arterial thrombosis in hyperhomocysteinaemia is low and mainly depends on concomitant thrombophilic defects

Willem M. Lijfering1, Michiel Coppens2, Marlène H. W. van de Poel1, Saskia Middeldorp2, Karly Hamulyák3, Ivan Bank2, Nic J. G. M. Veeger1, Martin H. Prins4, Harry R. Büller2, Jan van der Meer1

Thrombosis and Haemostasis 2007 98 2: 457-563

http://dx.doi.org/10.1160/TH07-02-0138

2.
Thrombin activation of endometrial endothelial cells: A possible role in intrauterine growth restriction

Graciela Krikun1, Se-Te Joseph Huang1, Frederick Schatz1, Carolyn Salafia2, Carlos Stocco1, Charles J Lockwood1

Thrombosis and Haemostasis 2007 97 2: 245-253

http://dx.doi.org/10.1160/TH06-07-0387

3.
The pharmacology of selective inhibition of COX-2

Tilo Grosser

Thrombosis and Haemostasis 2006 96 4: 393-400

http://dx.doi.org/10.1160/TH06-08-0444



Articles

You've 559 Article(s) in your Basket.

Thrombosis News

TH 107.5

Clinical Focus on GPIIb/IIIa inhibitors: In the May issue of Thrombosis and Haemostasis Armstrong...

TH 107.4

The April 2012 issue of Thrombosis and Haemostasis TH 107.4 is a Theme Issue by A. Schober, T....

Thrombosis and Haemostasis official organ of Spanish Society for Thrombosis and Haemostasis

Thrombosis and Haemostasis, founded in 1957, has become the official organ of the Spanish Society...